Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review.
Oliver Rumle HovmandEmil Deleuran PoulsenSidse ArnfredOle Jakob StorebøPublished in: Journal of psychopharmacology (Oxford, England) (2023)
Successful blinding of intervention is a significant challenge in this field. To better accommodate this, we suggest that future trials use a parallel-group design and utilize an active placebo on a psychedelic-naïve population. Future trials should publish trial protocol and SAPs, use clinician-rated outcomes accessed by a blinded rater, evaluate blinding of intervention, and consider measuring expectancy and therapeutic fidelity.